Access Enters RNAi Delivery Pact

Access Pharmaceuticals, Inc. has entered into an agreement with a major pharmaceutical company to use its CobaCyte and CobOral technology for the targeted delivery of RNAi therapeutics. Access will provide CobOral and CobaCyte siRNA formulations for evaluation of gene knockdown following oral and intravenous administration. According to Access, any successful formulation developed will be jointly owned and subject to a subsequent full licensing agreement. Terms of the agreement were not disclosed.

“We have made great progress in our CobOral and CobaCyte siRNA delivery programs over the past year, demonstrating the efficiency and safe delivery needed for a viable RNAi therapeutic,” said Jeffrey B. Davis, president and chief executive officer, Access Pharmaceuticals, Inc. “The signing of this agreement serves as further validation of our previous work related to our CobaCyte technology’s unique ability to deliver inactivated siRNA particles to disease target sites.We believe our innovative approach is well-suited for this pharmaceutical company and look forward to the collaborative work ahead.”